Company Filing History:
Years Active: 1996-1999
Title: Innovations by Winfried Stephan Wels in Recombinant Antibodies
Introduction
Winfried Stephan Wels, an accomplished inventor based in Basel, Switzerland, has made significant contributions to the field of biotechnology. His work predominantly focuses on the development of recombinant antibodies aimed at targeting specific growth factor receptors. With two patents to his name, Wels has played a crucial role in advancing medical diagnostics and therapies.
Latest Patents
Wels's most notable inventions include recombinant antibodies specific for the human growth factor receptor c-erbB-2. These antibodies include both a light chain variable domain and a heavy chain variable domain derived from monoclonal antibodies. The patents outline various methods involving the manufacturing of these recombinant antibodies, hybridoma cells that secrete monoclonal antibodies, and detailed processes for the use of the antibodies in diagnosing and treating tumors. His innovative approach combines genetic engineering with principles of immunology, highlighting the potential of these antibodies in clinical applications.
Career Highlights
Throughout his career, Winfried Stephan Wels has been affiliated with prominent companies such as Ciba-Geigy Corporation and Novartis Corporation. His experiences in these institutions have significantly shaped his research and development skills. Wels's patented inventions reflect his commitment to addressing medical challenges through innovative antibody therapies.
Collaborations
Wels has worked alongside esteemed colleagues such as Nancy E. Hynes and Bernd Groner. These collaborations have fostered a rich exchange of ideas and facilitated advancements in the understanding of antibody-based therapies. Together, they have contributed to an environment of innovation within the pharmaceutical and biotechnology sectors.
Conclusion
Winfried Stephan Wels stands out as a visionary inventor in the field of recombinant antibodies. His patented innovations not only enhance the understanding of cancer biology but also pave the way for more effective diagnostic and therapeutic options. Through his perseverance and collaborative spirit, Wels continues to inspire future innovations in biomedical research.